Tirzepatide Dosing Chart: 2.5 to 15 mg Schedule

Medically reviewed by Amber Patel, MD · Last updated July 15, 2026. Nouri content is reviewed by licensed clinicians and updated as guidance changes.

What is the standard tirzepatide dosing schedule?

Tirzepatide is a dual GIP/GLP-1 receptor agonist taken as a once-weekly injection, and its schedule follows the same start-low-climb-slow logic as every drug in this class — the difference is that its ladder is taller. The FDA-approved escalation for weight management (the Zepbound label, revision April 2026):

Weeks	Once-weekly dose	Purpose
1–4	2.5 mg	Treatment initiation — the label states it is not approved as a maintenance dosage
5–8	5 mg	First full step — also an approved maintenance dose for weight
9–12	7.5 mg	Escalation step only
13–16	10 mg	Escalation — approved maintenance dose
17–20	12.5 mg	Escalation step only
21+	15 mg	Maximum — approved maintenance dose

The week numbers show the fastest path the label allows, not a mandate. Each step requires at least four weeks on the current dose, and if a maintenance dose isn't tolerated, the label's instruction is plain: consider a lower maintenance dose. Real-world schedules routinely hold a dose for eight or twelve weeks — that's the system working, not falling behind.

Can you stay at 5 mg of tirzepatide long-term?

For weight management, yes — 5 mg is one of the three approved maintenance doses (5, 10, 15 mg), and staying there is a legitimate endpoint if it's delivering results you and your clinician are happy with. The intermediate doses are different: 7.5 mg and 12.5 mg exist to smooth the climb, not to live on.

One indication changes this math. Since December 2024, Zepbound is also FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity — the first medication approved for OSA — and for that indication the label names 10 mg or 15 mg as maintenance. The 5 mg long-term option is a weight-management provision, not an OSA one.

How is Mounjaro's schedule different?

Mounjaro is the same molecule labeled for type 2 diabetes, and the ladder mechanics are identical — 2.5 mg initiation, 2.5 mg increments, four-week minimums, 15 mg maximum. The difference is the trigger: Mounjaro's label escalates only if additional glycemic control is needed, rather than marching toward a target maintenance dose. There's no fixed 5/10/15 maintenance list; the dose is wherever glycemic response says it should be. (One more wrinkle: in pediatric patients, Mounjaro's maximum is 10 mg.)

What happens if you miss a dose of tirzepatide?

Tirzepatide's missed-dose rule is more forgiving than semaglutide's, and it's identical on both labels:

• Within 4 days (96 hours) of the missed dose: take it as soon as possible, then resume your regular day.
• More than 4 days later: skip it entirely and take the next dose on schedule. No doubling up.
• The spacing rule behind it: any two doses must be at least 3 days (72 hours) apart — which is also the rule that governs changing your injection day.

That 96-hour window means a forgotten Sunday shot taken on Wednesday is fine. What the label doesn't give you is a rule for missing several weeks — extended gaps mean a conversation with your prescriber about where on the ladder to resume, because GI tolerance fades when the medication does.

Compounded tirzepatide dosing: vials, units, and the conversion problem

Compounded tirzepatide programs follow the same 2.5-to-15 mg ladder — the molecule's pharmacology doesn't care about the packaging — but the packaging changes your week-to-week reality. Zepbound comes in six fixed-dose pens and vials; nothing to measure. Compounded tirzepatide usually arrives as a multi-dose vial you draw from with a U-100 insulin syringe, which makes every injection a mg-to-units conversion that depends on the vial's concentration:

Prescribed dose	10 mg/mL vial	17 mg/mL vial	20 mg/mL vial
2.5 mg	25 units (0.25 mL)	14.7 units (0.147 mL)	12.5 units (0.125 mL)
5 mg	50 units (0.5 mL)	29.4 units (0.294 mL)	25 units (0.25 mL)
10 mg	100 units (1 mL)	58.8 units (0.588 mL)	50 units (0.5 mL)

The stakes here are documented, not theoretical: the FDA's July 2024 alert on compounded injectable GLP-1 medications describes patients who drew five to twenty times their intended dose because units, milliliters, and milligrams got confused — and by April 2025 the agency had logged roughly 480 adverse-event reports tied to compounded tirzepatide. Our free tirzepatide dose calculator converts any prescribed dose to units and mL for every common vial concentration, with a visual syringe. The habit that matters most: verify the mg/mL on your own pharmacy label at every refill — concentrations change between batches, and a units number that was right last month can be wrong today.

Managing side effects during dose escalation

The pattern is consistent across every tirzepatide trial: GI side effects are common, mostly mild to moderate, and concentrated in the escalation phase. On the label's numbers, nausea affected 25–29% of participants (versus 8% on placebo), diarrhea 19–23%, vomiting 8–13%, constipation 11–17% — and the label states directly that the majority of nausea, vomiting, and diarrhea events occurred during dose escalation and decreased over time. In SURMOUNT-1, the trial behind the weight indication, the story was the same: GI events clustered in the 20-week escalation period.

Practically, that means the week after each step-up deserves some planning — lighter meals, more water, patience — and it means a rough transition is a reason to hold, not to quit. A fuller picture of what to expect and when it fades is in our guide to tirzepatide side effects. If a maintenance dose stays intolerable, stepping down is an approved, explicitly labeled option.

How does tirzepatide dosing compare with semaglutide?

The two ladders aren't interchangeable, and neither are the milligrams — 5 mg of tirzepatide is not "double" 2.4 mg of semaglutide; they're different molecules with different receptor activity and potency curves. That's why there is no label-defined conversion for switching: moving from semaglutide to tirzepatide means starting at 2.5 mg and climbing the tirzepatide ladder under your prescriber's guidance, regardless of where you were on the old one.

On effect, the head-to-head data is recent and clear-cut: in SURMOUNT-5 (2025), adults on tirzepatide at maximum tolerated dose lost on average 20.2% of body weight over 72 weeks versus 13.7% on semaglutide 2.4 mg — results for the branded molecules studied in that trial, not for compounded versions, which are not FDA-approved or shown to be equivalent. GI side-effect rates were similar in both arms, again concentrated during escalation. For a fuller side-by-side, see our comparison of compounded semaglutide vs tirzepatide — and if you're weighing the branded product against the compounded format, compounded tirzepatide vs Zepbound covers the real differences.

How dosing works in a telehealth program

The chart above is the reference; your schedule is whatever your prescriber writes, adjusted as your response and tolerance become clear. That adjustment loop is the part worth scrutinizing when you choose a provider — a prescription without follow-up leaves you alone at exactly the moments the ladder gets hard. At Nouri, a U.S.-licensed physician reviews your intake and, when appropriate, prescribes compounded tirzepatide with the titration plan built in; dose changes afterward are handled by messaging your Care Team, and every dose costs the same — so moving up (or holding) is a clinical decision with no billing consequence. Our page on tirzepatide telehealth explains that ongoing-care model, and the tirzepatide cost breakdown shows how per-dose surcharges elsewhere change the escalation math.

Frequently asked questions

How long do you stay on 2.5 mg of tirzepatide?

Four weeks, per the label — then the dose moves to 5 mg. The 2.5 mg dose is for treatment initiation and is not approved as a maintenance dose, so staying there long-term isn't the plan; it exists to build GI tolerance.

When do you move up to the next dose?

After at least four weeks on the current dose, when your prescriber decides more effect is warranted and you're tolerating the current step. Holding longer is common and label-sanctioned.

What is the maximum dose of tirzepatide?

15 mg once weekly, for both Zepbound and adult Mounjaro use. Approved maintenance doses for weight management are 5, 10, or 15 mg.

What if I miss a dose of tirzepatide?

Take it within 4 days (96 hours) of the missed dose; past that, skip it and resume your schedule. Never take two doses within 3 days (72 hours) of each other.

How many units is 2.5 mg of compounded tirzepatide?

It depends on your vial's concentration: 25 units from a 10 mg/mL vial, about 15 units from a 17 mg/mL vial, 12.5 units from a 20 mg/mL vial on a U-100 insulin syringe. Convert from the mg/mL on your own pharmacy label — never from someone else's numbers.

Is the dosing schedule the same for Zepbound and Mounjaro?

The ladder is the same — 2.5 mg start, 2.5 mg increments, four-week minimums, 15 mg max — but Mounjaro escalates only if more glycemic control is needed, while Zepbound climbs toward a weight-management maintenance dose of 5, 10, or 15 mg.

How do you switch from semaglutide to tirzepatide?

There's no label-defined conversion between the molecules. Switching means starting tirzepatide at 2.5 mg and titrating from there under your prescriber's guidance — the doses are not mg-for-mg interchangeable.

Sources

• Zepbound (tirzepatide) Prescribing Information — DailyMed, revised April 2026. dailymed.nlm.nih.gov
• Mounjaro (tirzepatide) Prescribing Information — DailyMed, revised April 2026. dailymed.nlm.nih.gov
• Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM 2022. nejm.org
• Aronne LJ et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). NEJM 2025. nejm.org
• FDA press announcement — first medication approved for obstructive sleep apnea (Zepbound), December 2024. fda.gov
• FDA alert — dosing errors associated with compounded injectable GLP-1 medications, July 2024. fda.gov
• FDA — Compounding and the FDA: Questions and Answers. fda.gov

Considering treatment? See if you qualify with Nouri — a five-minute health intake, reviewed by a U.S.-licensed physician. One all-inclusive price, the same at any dose.

Compounded tirzepatide is not FDA-approved and has not been evaluated by the FDA for safety, effectiveness, or quality, and is not therapeutically equivalent to Zepbound or Mounjaro. All dosing information above describes the FDA-approved product labels and published research; it is educational, not medical advice, and never a substitute for your prescriber's instructions. Nouri connects patients with licensed, independent physicians who make all prescribing decisions.